DekaBank Deutsche Girozentrale boosted its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 123.0% in the second quarter, according to the company in its most recent filing with the SEC. The firm owned 197,699 shares of the life sciences company’s stock after acquiring an additional 109,033 shares during the quarter. DekaBank Deutsche Girozentrale’s holdings in Illumina were worth $70,684,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also recently modified their holdings of ILMN. Thoroughbred Financial Services LLC lifted its holdings in shares of Illumina by 38,516.8% in the 2nd quarter. Thoroughbred Financial Services LLC now owns 875,828 shares of the life sciences company’s stock valued at $87,583,000 after buying an additional 873,560 shares during the period. American Century Companies Inc. raised its holdings in Illumina by 107.1% in the 1st quarter. American Century Companies Inc. now owns 815,875 shares of the life sciences company’s stock worth $253,484,000 after purchasing an additional 421,953 shares during the period. Nikko Asset Management Americas Inc. raised its holdings in Illumina by 242.2% in the 2nd quarter. Nikko Asset Management Americas Inc. now owns 416,303 shares of the life sciences company’s stock worth $153,262,000 after purchasing an additional 294,643 shares during the period. MERIAN GLOBAL INVESTORS UK Ltd raised its holdings in Illumina by 841.1% in the 1st quarter. MERIAN GLOBAL INVESTORS UK Ltd now owns 269,170 shares of the life sciences company’s stock worth $83,628,000 after purchasing an additional 240,569 shares during the period. Finally, Bessemer Group Inc. raised its holdings in Illumina by 8,816.3% in the 2nd quarter. Bessemer Group Inc. now owns 214,525 shares of the life sciences company’s stock worth $78,978,000 after purchasing an additional 212,119 shares during the period. 90.95% of the stock is owned by institutional investors.
A number of equities analysts recently weighed in on ILMN shares. UBS Group upped their price target on Illumina from $350.00 to $355.00 and gave the stock a “buy” rating in a report on Tuesday, July 30th. Wolfe Research started coverage on Illumina in a report on Thursday, May 30th. They issued an “outperform” rating for the company. ValuEngine raised Illumina from a “hold” rating to a “buy” rating in a report on Thursday, August 8th. Piper Jaffray Companies reduced their price target on Illumina from $382.00 to $348.00 and set an “overweight” rating for the company in a report on Tuesday, July 30th. Finally, Cowen cut their price objective on Illumina from $380.00 to $320.00 and set an “outperform” rating for the company in a research note on Friday, July 12th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and twelve have issued a buy rating to the company. Illumina currently has a consensus rating of “Buy” and a consensus target price of $330.92.
Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Monday, July 29th. The life sciences company reported $1.35 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.32 by $0.03. Illumina had a return on equity of 21.73% and a net margin of 27.56%. The company had revenue of $838.00 million during the quarter, compared to analyst estimates of $835.12 million. During the same period in the previous year, the business earned $1.43 EPS. Illumina’s quarterly revenue was up 1.0% on a year-over-year basis. Analysts anticipate that Illumina, Inc. will post 6.04 earnings per share for the current year.
In related news, SVP Mostafa Ronaghi sold 10,000 shares of the stock in a transaction that occurred on Monday, June 17th. The stock was sold at an average price of $349.28, for a total value of $3,492,800.00. Following the completion of the transaction, the senior vice president now directly owns 65,994 shares in the company, valued at $23,050,384.32. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Robert P. Ragusa sold 2,230 shares of the stock in a transaction that occurred on Thursday, August 8th. The stock was sold at an average price of $293.09, for a total value of $653,590.70. Following the completion of the transaction, the senior vice president now owns 10,685 shares of the company’s stock, valued at $3,131,666.65. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 50,458 shares of company stock valued at $16,527,618. 0.38% of the stock is owned by company insiders.
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.
Further Reading: Capital gains and your 401(k) or IRA
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.